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Pediatric Kidney Transplantation at the University of Pittsburgh 
V.P. Scantlebury, R. Shapiro, A. Tzakis, M.L. Jordan, C. Vivas, D. Ellis, N. Gilboa, L. Hopp, W. Irish, 
S. Mitchell, T.R. Hakala, R.L. Simmons, and T.E. Starzl 
THE RESULTS of pediatric kidney transplantation have varied over the years, with .outcomes ranging 
from fair to excellent. I The majority of centers performing 
pediatric kidney transplantation in the United States have 
shown patient and graft survival rates of 92% to 96% and 
74% to 89%, respectively.2 We describe here our own 
results with cadaveric and living related pediatric renal 
transplant recipients over a 5·year period. 
MATERIALS 
Sixty·three consecutive kidney transplants were performed in 62 
patients at Children's Hospital of Pittsburgh between Jan I. 1988. 
and Jan I. 1993 (Table I). Children with previous or simultaneous 
liver transplants were excluded. Thirty·five (56%) patients had 
living donors. while 28 (44%) received cadaveric kidneys. The 
mean age was 9.8 :!: 4.8 years (range, 0.8 to 17.4 years). Primary 
transplants were performed in 47 patients (75%). while 16 (25%) 
underwent retransplantatton. Only 9 patients (14%) had panel· 
reactive antibody levels of >40%. Thirty-three patients (52%) 
received cyclosporine as their main Immunosuppression. while 30 
patients (48%) received FK 506 (Table I). 
Living related transplants performed with cyclosporine (20 
patients) initially received induction Minnesota antiJymphoblast 
globulin (MALG), 20 mglkgld for 2 weeks along with azathioprine 
and prednisone. Cyclesporine was introduced at 5 mglkg twice a 
day starting at day 7. For cadaveric transplants performed with 
cyclosporine (\3 patients), 4 patients received induction OKT 3 at 
5 mgld for 2 weeks and I patient received induction MALG. 
Azathiopnne was also used in II patients on cyclosporine ther· 
apy. Thirty patients (15 living donors and 15 cadaveric) received 
FK 506 and this was gIven at 0.1 mglkgld as a continuous infusion 
foHowed by a 0.30 mglkgld oral dose in two divided doses. Twelve 
patients (40%) receIved azathioprine Initially with FK 506, and aU 
patients received steroids. 
RESULTS 
The median follow-up was 38 months (range, 6 to 67 
months). The 1- and 4-year actuarial patient survival rates 
Table 1. University of Pittsburgh Pediatric Kidney 
Transplantation (Jan 1, 1988, to Jan 1, 1993): 
Number 01 patients 
Number 01 grafts 
Living donor 
CadaveriC donor 
Mean reaplent age 
Primary transplants 
Retransplantation 
Recipient Characteristics 
Panel·reactive antibodies >40% 
Cyclosponne 
FK 506 
62 
63 
35 (56%) 
28 (44%) 
9.8 :!: 4.8 years 
47 (75%) 
16(25%) 
9 (14"10) 
33 (52%) 
30 (48%) 
Table 2. University of Pittsburgh Pediatric Kidney 
Transplantation (Jan 1,1988, to Jan 1, 1993): Survival Rates 
Patient Survival Graft Survival 
1 Year 4 Years 1 Year 4 Years 
Overall 100% 98% 98% 86% 
Cadaveric donor 100% 96% 96% 76% 
Living related donor 100% 100% 100% 95% 
Cyclosporine 100% 97% 100% 85% 
FK506 100% 100'Yo· 96% 89%· 
·Three years rather than 4. 
were 100% and 98%, respectively. The 1- and 4-year 
actuarial graft survival rates were 98% and 86% (Table 2). 
When cadaveric and living related patients were separated, 
patient survival rates were not significantly different at 1 
and 4 years (100% and 96% vs 100% and 100%, respec-
tively). Graft survival was shown to be a bit better for 
living related transplant recipients at I year and at 4 years 
when compared to cadaveric transplant recipients. Patient 
survival was essentially the same for cyclosporine-treated 
patients and FK 506-treated patients. There was also little 
difference in graft survival at 1 and 4 years with cyclospo-
rine (100% and 85%) vs 1 and 3 years with FK 506 (96% 
and 89%). 
One patient died, 1.5 years after his second cadaveric 
transplant, with a functioning graft. This patient had been 
treated with cyclosporine and died of cardiac abnormali-
ties. Five other patients lost their grafts: 2 to noncompli-
ance at 1.5 and 3 years after transplantation (with cYclo-
sporine), and 3 to recurrent disease (hemolytic uremic 
syndrome, focal segmental glomerulosclerosis, and mem-
brane proliferative glomerulonephritis) at 1 week and 3.5 
and 2.5 years after their transplants. 
Rejection was seen in 46% of the patients. Eighteen 
cadaveric transplant patients experienced rejection (64%), 
while 11 (31%) living related transplant patients rejected 
their grafts (P = .01). Cyc!osporine-treated patients had 
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39% rejection vs 53% for those patients who received FK 
506 (P = .237). 
Eighteen (60%) patients treated with FK 506 had pred-
nisone discontinued. No patient on cyclosporine was suc-
cessfully taken off prednisone long term. 
Six patients (10%) developed cytomegalovirus (CMV) 
infections (3 cadaveric and 3 living related patients). Five 
of 6 (83%) patients received FK 506 (P = .07), and nearly 
all patients (5 of 6) were at high risk for CMV infection 
(seropositive kidneys to seronegative recipients). 
Posttransplant lymphoproliferative disease was seen in 6 
patients (10%), 3 cadaveric and 3 living related. One 
patient had been treated with cyclosporine (3%), and 5 
patients (17%) received FK 506 immunosuppression (P = 
.07). All patients were treated with cessation or diminution 
of their immunosuppression, along with intravenous acy-
clovir or ganciclovir. No grafts were lost. and all patients 
recovered. 
Four patients were switched from cyclosporine to FK 
506: 1 for rejection and 3 for proteinuria. The patient with 
rejection was successfully rescued and 1 patient with 
proteinuria had significant improvement in protein excre-
tion with FK 506. The remaining 2 patients lost their grafts 
to recurrent disease. 
DISCUSSION 
Pediatric patient survival after kidney transplantation did 
not vary significantly regardless of donor source or type of 
immunosuppression. Results of graft survival at 4 years for 
cadaveric transplants, although above average, were not 
as good as for those patients who received a kidney from 
a living related donor (76% vs 95%). Likewise, more 
episodes of rejection were seen in the cadaveric patients 
47 
when compared to the living related patients. Although FK 
506-treated patients had slightly more rejection episodes, 
60% of this group had the ability to discontinue pred-
nisone. For pediatric recipients. this allows for long-term 
growth and development after transplantation, and there 
are some preliminary data from this center suggesting that 
there is improvement in growth for those patients treated 
only with FK 506 in the long term.) 
The increased incidence of CMV infection and post-
transplant lymphoproliferative disease seen with patients 
treated with FK 506 is significant when compared to that in 
the cyclosporine-treated patients. Fortunately, these com-
plications all resolved without any significant sequelae or 
graft losses. These findings may represent a learning curve 
with the use of FK 506 in renal transplant recipients, as 
described in our own experience with adult patients.4 
Overall, our data support the improved results of pedi-
atric kidney transplants and suggest that newer agents 
such as FK 506, with the ability to discontinue the use. of 
steroids after transplantation can be very useful, especially 
for this population of patients. Further work to decrease 
the long-term side effects of chronic immunosuppression 
should still be a primary focus to optimize the long-term 
outcome of pediatric kidney transplantation. 
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